Business
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-
About this update from Assembly Biosciences, Inc.
[{"type":"image","alt":"Assembly Biosciences, Inc.","displaySize":"","headline":null,"caption":"Assembly Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J6r3DLbchgNACu.nMrU._Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3/https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8","width":300,"height":62}},"lazy":false},{"type":"text","content":"– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –","length":119,"tagName":"p"},{"type":"text","content":"– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –","length":77,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-primase inhibitor candidates, will be featured in multiple presentations, including one late-breaker, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany.","length":558,"tagName":"p"},{"type":"text","content":"“The selection of ABI-5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “We are also pleased to see the first scientific presentation of Phase 1b data for ABI-1179 recognized as a late-breaker presentation, which highlight its potential as a long-acting therapeutic option for patients with recurrent genital herpes.”","length":511,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"ABI-5366:","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Oral Presentation: ABI-5366-101: a phase 1b study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpesPre...